Literature DB >> 19300292

Neurophysiological characterization of high-dose magnetic seizure therapy: comparisons with electroconvulsive shock and cognitive outcomes.

Yael M Cycowicz1, Bruce Luber, Timothy Spellman, Sarah H Lisanby.   

Abstract

Magnetic seizure therapy (MST) is under development as a means of improving cognitive outcomes with convulsive therapy through achieving better control over therapeutic seizure induction than is possible with conventional electroconvulsive therapy. In this investigation, we present the first neurophysiological characterization of high-dose MST (HD-MST, 6x seizure threshold) to see if a higher dose that is often used in human trials retains differential expression relative to electroconvulsive shock (ECS) and to explore the relationship between seizure expression and cognitive outcomes. To this end, rhesus monkeys received 4 weeks of daily treatment with ECS, HD-MST, and anesthesia-alone sham in counterbalanced order, with an interposed recovery period. Two channels of electroencephalogram were recorded during and immediately after the ictal period. Electroencephalogram power within delta, theta, alpha, and beta frequency bands was calculated. Electroconvulsive shock showed significantly more ictal power in all frequency bands than HD-MST (P < 0.01). Electroencephalogram power during the postictal period was significantly different among conditions only for the delta band. Higher ictal expression with ECS was associated with slowed completion time for an orientation task given immediately after the treatments. Our results support earlier findings demonstrating that MST- and ECS-induced seizures elicit differential patterns of ictal expression, consistent with the relatively more superficial stimulation achieved via magnetic induction in comparison with conventional electroconvulsive therapy. These results demonstrate that MST, even at high dose, results in seizures that differ neurophysiologically from ECS. It further suggests that some of the differences in ictal expression may relate to the improved cognitive outcomes seen with MST.

Entities:  

Mesh:

Year:  2009        PMID: 19300292     DOI: 10.1097/YCT.0b013e31818dd40a

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  11 in total

1.  Electroconvulsive therapy: How modern techniques improve patient outcomes: Refinements have decreased memory loss, other adverse effects while retaining efficacy: Refinements have decreased memory loss, other adverse effects while retaining efficacy.

Authors:  Owais Tirmizi; Ahmad Raza; Kenneth Trevino; Mustafa M Husain
Journal:  Curr Psychiatr       Date:  2012-10

2.  A systematic review of the neurocognitive effects of magnetic seizure therapy.

Authors:  Shawn M McClintock; Owais Tirmizi; Matthieu Chansard; Mustafa M Husain
Journal:  Int Rev Psychiatry       Date:  2011-10

3.  Individualized Low-Amplitude Seizure Therapy: Minimizing Current for Electroconvulsive Therapy and Magnetic Seizure Therapy.

Authors:  Angel V Peterchev; Andrew D Krystal; Moacyr A Rosa; Sarah H Lisanby
Journal:  Neuropsychopharmacology       Date:  2015-04-28       Impact factor: 7.853

4.  Differential heart rate response to magnetic seizure therapy (MST) relative to electroconvulsive therapy: a nonhuman primate model.

Authors:  Stefan B Rowny; Yael M Cycowicz; Shawn M McClintock; Matthew D Truesdale; Bruce Luber; Sarah H Lisanby
Journal:  Neuroimage       Date:  2009-06-02       Impact factor: 6.556

Review 5.  Translational development strategy for magnetic seizure therapy.

Authors:  Stefan B Rowny; Karla Benzl; Sarah H Lisanby
Journal:  Exp Neurol       Date:  2009-04-05       Impact factor: 5.330

6.  Controlling stimulation strength and focality in electroconvulsive therapy via current amplitude and electrode size and spacing: comparison with magnetic seizure therapy.

Authors:  Zhi-De Deng; Sarah H Lisanby; Angel V Peterchev
Journal:  J ECT       Date:  2013-12       Impact factor: 3.635

7.  Brain stimulation in posttraumatic stress disorder.

Authors:  Vladan Novakovic; Leo Sher; Kyle A B Lapidus; Janet Mindes; Julia A Golier; Rachel Yehuda
Journal:  Eur J Psychotraumatol       Date:  2011-10-17

8.  Neuromodulation therapies and treatment-resistant depression.

Authors:  Khalid Saad Al-Harbi; Naseem Akhtar Qureshi
Journal:  Med Devices (Auckl)       Date:  2012-07-13

9.  Applications of transcranial magnetic stimulation and magnetic seizure therapy in the study and treatment of disorders related to cerebral aging.

Authors:  Bruce Luber; Shawn M McClintock; Sarah H Lisanby
Journal:  Dialogues Clin Neurosci       Date:  2013-03       Impact factor: 5.986

Review 10.  Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines.

Authors:  Simone Rossi; Andrea Antal; Sven Bestmann; Marom Bikson; Carmen Brewer; Jürgen Brockmöller; Linda L Carpenter; Massimo Cincotta; Robert Chen; Jeff D Daskalakis; Vincenzo Di Lazzaro; Michael D Fox; Mark S George; Donald Gilbert; Vasilios K Kimiskidis; Giacomo Koch; Risto J Ilmoniemi; Jean Pascal Lefaucheur; Letizia Leocani; Sarah H Lisanby; Carlo Miniussi; Frank Padberg; Alvaro Pascual-Leone; Walter Paulus; Angel V Peterchev; Angelo Quartarone; Alexander Rotenberg; John Rothwell; Paolo M Rossini; Emiliano Santarnecchi; Mouhsin M Shafi; Hartwig R Siebner; Yoshikatzu Ugawa; Eric M Wassermann; Abraham Zangen; Ulf Ziemann; Mark Hallett
Journal:  Clin Neurophysiol       Date:  2020-10-24       Impact factor: 4.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.